New CAR-T therapy shows promise for tough leukemia in Real-World study
NCT ID NCT07637929
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 200 Chinese patients with relapsed or refractory B-cell acute lymphoblastic leukemia who receive a CAR-T cell therapy called puzolcabtagene autoleucel. The goal is to see how well it works in everyday medical practice, measuring response rates and how long benefits last. The therapy uses a patient's own immune cells, modified to target and kill cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Puzolcabtagene autoleucel (a CAR-T cell therapy made from the patient's own immune cells)
- What this could lead to
- If successful, this could provide a treatment option for patients with hard-to-treat B-cell acute lymphoblastic leukemia, potentially leading to remission.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. CAR-T therapies can cause serious side effects like cytokine release syndrome. The study is early-stage and focused on real-world data, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.